Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias

被引：12

作者：

Brendel, J ^{[1
]}

Peukert, S ^{[1
]}

机构：

[1] Aventis Pharma Deutschland GMBH, Med Chem, D-65926 Frankfurt, Germany

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2002年 / 12卷 / 11期

关键词：

arrhythmia; atrial fibrillation; IKur; Kv1.5; potassium channel blockers;

D O I：

10.1517/13543776.12.11.1589

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Atrial arrhythmias are a common problem in cardiological practice. Despite the availability of several antiarrhythmic drugs there is a medical need for safer and more efficient treatments. The voltage-gated potassium channel Kv1.5 is regarded as a promising target for the development of new atrial selective drugs with fewer side effects. This review summarises patents claiming such compounds.-The chemistry and biological data disclosed in these patents are discussed in light of recent work demonstrating the antiarrhythmic effects of Kv1.5 blockers in vivo.

引用

页码：1589 / 1598

页数：10

共 50 条

[31] Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel
Beshore, Douglas C.
Liverton, Nigel J.
McIntyre, Charles J.
Claiborne, Christopher F.
Libby, Brian
Culberson, J. Christopher
Salata, Joseph J.
Regan, Christopher P.
Lynch, Joseph J.
Kiss, Laszlo
Spencer, Robert H.
Kane, Stephanie A.
White, Rebecca B.
Yeh, Suzie
Hartman, George D.
Dinsmore, Christopher J.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (08) : 2493 - 2496
[32] Cibenzoline attenuates upregulation of Kv1.5 channel gene expression by experimental paroxysmal atrial fibrillation
Yamashita, T
Sekiguchi, A
Iwasaki, YK
Sagara, K
Hatano, S
Iinuma, H
Aizawa, T
Fu, LT
INTERNATIONAL HEART JOURNAL, 2005, 46 (02) : 279 - 288
[33] Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers
Wu, Shengde
Fluxe, Andrew
Sheffer, Jim
Janusz, John M.
Blass, Benjamin E.
White, Ron
Jackson, Chris
Hedges, Richard
Murawsky, Michael
Fang, Bin
Fadayel, Gina M.
Hare, Michelle
Djandjighian, Laurent
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (24) : 6213 - 6218
[34] Antiarrhythmic drug-induced internalization of the atrial specific K plus channel, Kv1.5
Schumacher, Sarah Marie
McEwen, Dyke P.
Zhang, Lian
Arendt, Kristin L.
Van Genderen, Kristin M.
Martens, Jeffrey R.
FASEB JOURNAL, 2009, 23
[35] Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks Kv1.5 channels, for the potential treatment of atrial fibrillation
Billman, George E.
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (09) : 1048 - 1058
[36] Discovery and synthesis of tetrahydroindolone-derived carbamates as Kv1.5 blockers
Fluxe, Andrew
Wu, Shengde
Sheffer, James B.
Janusz, John M.
Murawsky, Michael
Fadayel, Gina M.
Fang, Bin
Hare, Michelle
Djandjighian, Laurent
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (22) : 5855 - 5858
[37] Computational Study of the Loss-of-Function Mutations in the Kv1.5 Channel Associated with Atrial Fibrillation
Rashid, Md Harunur
Kuyucak, Serdar
ACS OMEGA, 2018, 3 (08): : 8882 - 8890
[38] Discovery and synthesis of tetrahydroindolone derived semicarbazones as selective Kv1.5 blockers
Wu, Shengde
Fluxe, Andrew
Janusz, John M.
Sheffer, James B.
Browning, Greg
Blass, Benjamin
Cobum, Keith
Hedges, Richard
Murawsky, Michael
Fang, Bin
Fadayel, Gina M.
Hare, Michelle
Djandjighian, Laurent
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (22) : 5859 - 5863
[39] Remodeling of Kv1.5 Channel in Right Atria from Han Chinese Patients with Atrial Fibrillation
Ou, Xian-hong
Li, Miao-ling
Liu, Rui
Fan, Xin-rong
Mao, Liang
Fan, Xue-hui
Yang, Yan
Zeng, Xiao-rong
MEDICAL SCIENCE MONITOR, 2015, 21 : 1207 - 1213
[40] DOES KV1.5 CONTRIBUTE TO ATRIAL REPOLARIZATION IN FERRET HEART
FERMINI, B
SCHWEGEL, T
JOW, B
GUINOSSO, PJ
JURKIEWICZ, NK
FOLANDER, KL
SWANSON, RJ
SALATA, JJ
CIRCULATION, 1995, 92 (08) : 2748 - 2748

← 1 2 3 4 5 →